Breaking Down SG&A Expenses: Pfizer Inc. vs ImmunityBio, Inc.

A Comparative Analysis of SG&A Expenses: Pfizer Inc. vs ImmunityBio, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants like Pfizer Inc. and emerging players such as ImmunityBio, Inc. is crucial. Over the past decade, Pfizer's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of ImmunityBio, highlighting a strategic focus on expansive operations and marketing. In 2023, Pfizer's SG&A expenses were approximately 115 times greater than ImmunityBio's, reflecting its global reach and extensive product portfolio.

From 2014 to 2023, Pfizer's SG&A expenses showed a slight decline, with a notable dip in 2020, possibly due to pandemic-related operational shifts. Conversely, ImmunityBio's expenses fluctuated, peaking in 2015 and 2021, indicating strategic investments in growth and innovation. This financial juxtaposition underscores the diverse approaches within the pharmaceutical sector, where established firms and newcomers navigate distinct paths to success.